Medplus Health [MEDPLUS] vs Strides Pharma [STAR] Detailed Stock Comparison
Medplus Health
NSE
Loading...
Strides Pharma
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Medplus Health wins in 7 metrics, Strides Pharma wins in 12 metrics, with 0 ties. Strides Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Medplus Health | Strides Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 54.22 | 23.36 | Strides Pharma |
| Price-to-Book Ratio | 5.49 | 3.13 | Strides Pharma |
| Debt-to-Equity Ratio | 64.36 | 72.67 | Medplus Health |
| PEG Ratio | 53.18 | 0.56 | Strides Pharma |
| EV/EBITDA | 29.79 | 12.28 | Strides Pharma |
| Profit Margin (TTM) | 2.88% | 7.38% | Strides Pharma |
| Operating Margin (TTM) | 4.22% | 15.11% | Strides Pharma |
| EBITDA Margin (TTM) | 4.22% | 15.11% | Strides Pharma |
| Return on Equity | 8.64% | 138.93% | Strides Pharma |
| Return on Assets (TTM) | 4.47% | 59.41% | Strides Pharma |
| Free Cash Flow (TTM) | $4.81B | $4.42B | Medplus Health |
| Dividend Yield | N/A | 0.74% | N/A |
| 1-Year Return | 26.72% | -31.82% | Medplus Health |
| Price-to-Sales Ratio (TTM) | 1.56 | 1.73 | Medplus Health |
| Enterprise Value | $103.80B | $97.09B | Medplus Health |
| EV/Revenue Ratio | 1.68 | 2.10 | Medplus Health |
| Gross Profit Margin (TTM) | 26.12% | 60.32% | Strides Pharma |
| Revenue per Share (TTM) | $518 | $503 | Medplus Health |
| Earnings per Share (Diluted) | $14.83 | $37.13 | Strides Pharma |
| Beta (Stock Volatility) | 0.69 | 0.57 | Strides Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Medplus Health vs Strides Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Medplus Health | 1.21% | -3.02% | -7.43% | -0.80% | 12.29% | -4.09% |
| Strides Pharma | 3.21% | 12.13% | -1.63% | 35.19% | 38.74% | 27.10% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Medplus Health | 26.72% | 13.27% | -24.37% | -24.37% | -24.37% | -24.37% |
| Strides Pharma | -31.82% | 155.68% | 46.19% | -28.86% | 116.54% | 199.26% |
Performance & Financial Health Analysis: Medplus Health vs Strides Pharma
| Metric | MEDPLUS | STAR |
|---|---|---|
| Market Information | ||
| Market Cap | ₹96.37B | ₹79.94B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 358,057 | 444,392 |
| 90 Day Avg. Volume | 202,418 | 490,137 |
| Last Close | ₹813.80 | ₹895.15 |
| 52 Week Range | ₹616.00 - ₹1,045.30 | ₹513.05 - ₹1,675.00 |
| % from 52W High | -22.15% | -46.56% |
| All-Time High | ₹1,343.00 (Jan 17, 2022) | ₹1,675.00 (Oct 14, 2024) |
| % from All-Time High | -39.40% | -46.56% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.03% |
| Quarterly Earnings Growth | 1.95% | 0.42% |
| Financial Health | ||
| Profit Margin (TTM) | 0.03% | 0.07% |
| Operating Margin (TTM) | 0.04% | 0.15% |
| Return on Equity (TTM) | 0.09% | 1.39% |
| Debt to Equity (MRQ) | 64.36 | 72.67 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹146.47 | ₹276.88 |
| Cash per Share (MRQ) | ₹30.67 | ₹21.55 |
| Operating Cash Flow (TTM) | ₹3.31B | ₹36.02B |
| Levered Free Cash Flow (TTM) | ₹1.50B | ₹35.93B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.74% |
| Last 12-Month Dividend | N/A | ₹6.50 |
Valuation & Enterprise Metrics Analysis: Medplus Health vs Strides Pharma
| Metric | MEDPLUS | STAR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 54.22 | 23.36 |
| Forward P/E | 53.18 | 13.48 |
| PEG Ratio | 53.18 | 0.56 |
| Price to Sales (TTM) | 1.56 | 1.73 |
| Price to Book (MRQ) | 5.49 | 3.13 |
| Market Capitalization | ||
| Market Capitalization | ₹96.37B | ₹79.94B |
| Enterprise Value | ₹103.80B | ₹97.09B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.68 | 2.10 |
| Enterprise to EBITDA | 29.79 | 12.28 |
| Risk & Other Metrics | ||
| Beta | 0.69 | 0.57 |
| Book Value per Share (MRQ) | ₹146.47 | ₹276.88 |
Financial Statements Comparison: Medplus Health vs Strides Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MEDPLUS | STAR |
|---|---|---|
| Revenue/Sales | ₹15.43B | ₹11.20B |
| Cost of Goods Sold | ₹11.40B | ₹4.44B |
| Gross Profit | ₹4.03B | ₹6.75B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹651.12M | ₹1.69B |
| EBITDA | ₹1.46B | ₹2.27B |
| Pre-Tax Income | ₹527.66M | ₹1.22B |
| Income Tax | ₹104.23M | ₹164.50M |
| Net Income (Profit) | ₹423.43M | ₹1.06B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MEDPLUS | STAR |
|---|---|---|
| Cash & Equivalents | ₹860.52M | ₹1.13B |
| Total Current Assets | ₹18.44B | ₹31.02B |
| Total Current Liabilities | ₹5.77B | ₹25.92B |
| Long-Term Debt | ₹10.08B | ₹6.23B |
| Total Shareholders Equity | ₹17.40B | ₹25.86B |
| Retained Earnings | N/A | ₹4.59B |
| Property, Plant & Equipment | ₹12.49B | ₹8.81B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MEDPLUS | STAR |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MEDPLUS | STAR |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 358,057 | 444,392 |
| Average Daily Volume (90 Day) | 202,418 | 490,137 |
| Shares Outstanding | 119.64M | 92.16M |
| Float Shares | 69.21M | 56.69M |
| % Held by Insiders | 0.42% | 0.33% |
| % Held by Institutions | 0.35% | 0.25% |
Dividend Analysis & Yield Comparison: Medplus Health vs Strides Pharma
| Metric | MEDPLUS | STAR |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹6.50 |
| Last 12-Month Dividend Yield | N/A | 0.74% |
| 3-Year Avg Annual Dividend | N/A | ₹2.67 |
| 3-Year Avg Dividend Yield | N/A | 0.32% |
| 3-Year Total Dividends | N/A | ₹8.00 |
| Ex-Dividend Date | N/A | Jul 22, 2025 |